These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35263859)

  • 21. Effect of Conscious Sedation vs General Anesthesia on Early Neurological Improvement Among Patients With Ischemic Stroke Undergoing Endovascular Thrombectomy: A Randomized Clinical Trial.
    Schönenberger S; Uhlmann L; Hacke W; Schieber S; Mundiyanapurath S; Purrucker JC; Nagel S; Klose C; Pfaff J; Bendszus M; Ringleb PA; Kieser M; Möhlenbruch MA; Bösel J
    JAMA; 2016 Nov; 316(19):1986-1996. PubMed ID: 27785516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy.
    Law ZK; Tan HJ; Chin SP; Wong CY; Wan Yahya WNN; Muda AS; Zakaria R; Ariff MI; Ismail NA; Cheong SK; S Abdul Wahid SF; Mohamed Ibrahim N
    Cytotherapy; 2021 Sep; 23(9):833-840. PubMed ID: 33992536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Citicoline in acute ischemic stroke: A randomized controlled trial.
    Agarwal A; Vishnu VY; Sharma J; Bhatia R; Garg A; Dwivedi S; Upadhyay A; Goyal V; Singh MB; Gupta A; Rajan R; Srivastava MVP
    PLoS One; 2022; 17(5):e0269224. PubMed ID: 35639720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of intravenous ginkgolide on clinical improvement of patients with acute ischemic stroke.
    Dong Y; Li H; Dong Q
    Neurol Res; 2020 Mar; 42(3):260-266. PubMed ID: 32048567
    [No Abstract]   [Full Text] [Related]  

  • 25. Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study.
    Chabriat H; Bassetti CL; Marx U; Picarel-Blanchot F; Sors A; Gruget C; Saba B; Wattez M; Audoli ML; Hermann DM
    Trials; 2020 Feb; 21(1):136. PubMed ID: 32014032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients.
    Spokoyny I; Raman R; Ernstrom K; Meyer BC; Hemmen TM
    J Stroke Cerebrovasc Dis; 2014; 23(5):1046-50. PubMed ID: 24103663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High neutrophil-to-lymphocyte ratio is a predictor of poor short-term outcome in patients with mild acute ischemic stroke receiving intravenous thrombolysis.
    Liu YL; Wu ZQ; Qu JF; Qiu DH; Luo GP; Yin HP; Fang XW; Wang F; Chen YK
    Brain Behav; 2020 Dec; 10(12):e01857. PubMed ID: 32981201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials.
    Dávalos A; Castillo J; Alvarez-Sabín J; Secades JJ; Mercadal J; López S; Cobo E; Warach S; Sherman D; Clark WM; Lozano R
    Stroke; 2002 Dec; 33(12):2850-7. PubMed ID: 12468781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NXY-059 for acute ischemic stroke.
    Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
    N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial.
    Ni J; Chen H; Chen G; Ji Y; Yi F; Zhang Z; Yang Y; Wu J; Cai X; Shao B; Wang J; Liu Y; Geng D; Qu X; Li X; Wei Y; Ding J; Lü H; Huang Y; Huang Y; Xiao B; Gong T; Cui L;
    BMC Neurol; 2020 Jul; 20(1):282. PubMed ID: 32664877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience.
    Koennecke HC; Nohr R; Leistner S; Marx P
    Stroke; 2001 May; 32(5):1074-8. PubMed ID: 11340212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.
    Donnan GA; Davis SM; Chambers BR; Gates PC; Hankey GJ; McNeil JJ; Rosen D; Stewart-Wynne EG; Tuck RR
    JAMA; 1996 Sep; 276(12):961-6. PubMed ID: 8805730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Citicoline for treating people with acute ischemic stroke.
    Martí-Carvajal AJ; Valli C; Martí-Amarista CE; Solà I; Martí-Fàbregas J; Bonfill Cosp X
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013066. PubMed ID: 32860632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients.
    Clark WM; Wechsler LR; Sabounjian LA; Schwiderski UE;
    Neurology; 2001 Nov; 57(9):1595-602. PubMed ID: 11706098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyper-acute EEG alterations predict functional and morphological outcomes in thrombolysis-treated ischemic stroke: a wireless EEG study.
    Ajčević M; Furlanis G; Naccarato M; Miladinović A; Buoite Stella A; Caruso P; Cillotto T; Accardo A; Manganotti P
    Med Biol Eng Comput; 2021 Jan; 59(1):121-129. PubMed ID: 33274407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial.
    Hong JM; Choi MH; Sohn SI; Hwang YH; Ahn SH; Lee YB; Shin DI; Chamorro Á; Choi DW;
    Trials; 2018 Jul; 19(1):375. PubMed ID: 30005644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial.
    Shyu WC; Lin SZ; Lee CC; Liu DD; Li H
    CMAJ; 2006 Mar; 174(7):927-33. PubMed ID: 16517764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
    Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
    J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
    Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
    Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.